Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic Wounds (CHITOWOUND)
A Randomized, Parallel, Double Blind, Placebo Controlled, Multicentre, Two Arms Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic Wounds
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zagreb, Croatia, 10000
- University Clinic Vuk Vrhovac
-
-
-
-
-
Celje, Slovenia, 3000
- General Hospital Celje
-
Kranj, Slovenia, 4000
- Clinic Golnik - Diabetic Clinic Kranj
-
Ljubljana, Slovenia, 1000
- University Hospital Center Ljubljana
-
Murska Sobota, Slovenia, 9000
- General Hospital Murska Sobota
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be given
- Patient ≥ 18 years old
- Diagnosed with type I or type II diabetes mellitus
- Glycosylated haemoglobin, HbA1c, ≤ 12%
Presence of diabetic foot ulcer or an amputation wound that meets following criteria:
- Size of the wound 0,5 - 12 cm^2
- Wagner grade I or II
- Wound is not infected
- Wound present for at least 4 weeks
- If multiple wounds are present, the biggest wound fitting the criteria is selected and the distance from other wounds must be at least 2 cm
- If there is an amputation wound present, it can be used for the purpose of this study if it fits the rest of the criteria
- Adequate perfusion (good, strong foot pulses). If foot pulses are weak, evaluation of perfusion pressures with Doppler ultrasound is performed.
- Able to understand and comply with the requirements of the trial
Exclusion Criteria:
- Known history of alcohol or drug abuse
- Use of any antibiotic medication within the last 7 days prior to the first application of study product
- Patients presenting with Wagner Grade III or higher ulcer
- Patients with serious concomitant disease (cancer, heart failure ( NYHA class IV), severe anemia (Hb<100 g/L), neoplasia)
- Any significant condition that may preclude the participant from the study (e.g. severe depression or psychiatric illness)
- Patients that will require surgical procedure to treat their ischemic condition on the limb where the wound is present as assessed by the doctor
- Excessive lymphedema that could interfere with wound healing (if there is mild edema treated with compression therapy the patient can be included)
- Patients diagnosed with autoimmune connective tissues diseases
- Previous treatment under this clinical protocol
- Participation in another clinical trial up to 30 days before the randomization visit.
- Receiving or scheduled to receive a medication or treatment which, in the opinion of the investigator, was known to interfere with, or affect the rate and quality of wound healing
- Medical condition likely to require systemic corticosteroids during the study period
- Allergic to shellfish, chitosan or one of ChitoCare product compounds
- Immobile patients
- Pregnant and lactating women
- Significant increase in wound healing during run-in period (reduction of wound size area ≥ 40%)
- BMI > 39 kg/m2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A (Experimental group
ChitoCare gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
|
ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
|
|
Placebo Comparator: Arm B (Control group)
Placebo gel administered topically 2-3 times a week or more (accordingly with the frequency of dressing change)
|
Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in proportions of ulcers completely healed for experimental group compared to control group.
Time Frame: 10 weeks
|
Relative healing rate (ratio between the proportion of ulcers healed for experimental group to proportion of ulcers healed in control group (= healing rate)).
|
10 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in proportion of ulcers completely healed for experimental group compared to the control group
Time Frame: 2, 4, 6 and 8 weeks
|
Relative healing rate (ratio between the proportion of ulcers healed for experimental group to the proportion of ulcers healed in control group)
|
2, 4, 6 and 8 weeks
|
|
Difference in reduction of diabetic ulcer wound size for experimental group compared to control group.
Time Frame: 2, 4, 6, 8, 10 and 14 weeks
|
Relative reduction of wound surface area.
|
2, 4, 6, 8, 10 and 14 weeks
|
|
Difference in time to complete healing for experimental group compared to control group.
Time Frame: Baseline to 14 weeks (whole study duration)
|
Hazard ratio for time to complete healing (experimental group vs. control group)
|
Baseline to 14 weeks (whole study duration)
|
|
Difference in improved quality of life for experimental group compared to control group.
Time Frame: 4 weeks and 10 weeks
|
The relative improvement of quality of life from the baseline value using the 36-Item Short Form Survey (SF-36) questionnaire (RAND Corporation).
|
4 weeks and 10 weeks
|
|
Difference in improved state of the wound for experimental group compared to control group using Bates-Jensen wound assessment tool (BWAT).
Time Frame: 2, 4, 6, 8, 10 and 14 weeks
|
The relative improvement of the state of the wound using Bates-Jensen wound assessment tool (BWAT).
|
2, 4, 6, 8, 10 and 14 weeks
|
|
Difference in improved state of the wound for experimental group compared to control group according to Wagner Ulcer Classification.
Time Frame: 2, 4, 6, 8, 10 and 14 weeks
|
The relative improvement of the state of the wound using Wagner Ulcer Classification.
|
2, 4, 6, 8, 10 and 14 weeks
|
|
Secondary infections that may occur during the study for experimental group compared to control group.
Time Frame: Baseline to 14 weeks (whole study duration)
|
Occurrence of secondary infection.
|
Baseline to 14 weeks (whole study duration)
|
|
Incidence of treatment related adverse events for experimental group compared to control group.
Time Frame: Baseline to 14 weeks (whole study duration)
|
The incidence of treatment related adverse events.
|
Baseline to 14 weeks (whole study duration)
|
|
To track diabetic ulcer recurrence for experimental group compared to control group in patients whose wound completely healed.
Time Frame: Baseline to 14 weeks (whole study duration)
|
The incidence of diabetic ulcer recurrence.
|
Baseline to 14 weeks (whole study duration)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Maja Navodnik Preložnik, MD, General Hospital Celje, Slovenia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHITO-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.